Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...

The following is a summary of “Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing ...

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...

5 This can cause neurological symptoms such as the following 6 ... is also observed in a smaller percentage of diffuse large B-cell lymphoma and other B-cell lymphomas. 2 Therefore, analysis ...

Basel: Roche has announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) ...

Hodgkin lymphoma is a type of lymphoma (a cancer originating ... distinct circulating and tumor-infiltrating CD4 + T cell, B cell and IL1β + monocyte/macrophage features associated with response ...

The study aims to evaluate the efficacy of SynKIR-310 in B-cell non-Hodgkin lymphoma subtypes such as diffuse large ... and it acts faster to alleviate cold symptoms. The light green oval soft capsule ...

Here's the scoop on the treatment, diagnosis, and definition of the primary brain lymphoma that landed Raphael in the ...

Dr Raj Arora, who regularly appears on shows such as ITV's This Morning to share health advice, recently shared five common ...